分子診断における自動化市場：タイプ、自動化タイプ、製品、用途、最終用途別-2025～2030年の世界予測

分子診断における自動化市場は、2023年に117億5,000万米ドルと評価され、2024年には135億4,000万米ドルに達すると予測され、CAGR 15.79％で成長し、2030年には328億1,000万米ドルに達すると予測されています。

分子診断における自動化とは、様々な医療研究目的の分子の検出・分析に関わるプロセスを合理化・強化するための先進技術と自動化システムの統合を指します。このセグメントにおける自動化の必要性は、より高い精度、エラーの低減、処理時間の短縮、スループットの向上に対するニーズによってもたらされます。自動化の応用は、サンプル調製、アッセイ開発、データ分析、結果解釈に及び、検査室、病院、研究機関に大きな利益をもたらします。最終用途の範囲は広く、臨床診断、創薬、個別化医療、疫学に対応しています。

市場洞察によると、主要成長要因としては、慢性疾患の有病率の上昇、個別化医療に対する需要の増加、診断機器の技術的進歩などが挙げられます。さらに、人工知能と機械学習の統合によって新たなビジネス機会がもたらされ、診断プロセスにおけるデータ解釈と業務効率の革新が約束されています。企業は、AI主導型プラットフォームの研究開発に投資し、戦略的パートナーシップを結んで専門知識と市場リーチを強化することで、こうした機会を捉えることができます。

しかし、市場は、導入コストの高さ、規制上のハードル、データのプライバシーと管理をめぐる倫理的懸念などの制約に直面しています。こうした課題に対処するには、費用対効果の高いソリューションと強固なサイバーセキュリティ対策を開発し、コンプライアンスを確保するための明確な規制の枠組みを構築する必要があります。

技術革新のセグメントとしては、ポイントオブケア検査ソリューションの開発、改良型バイオセンサー、診断サービスの分散化と迅速化を約束するラボオンチップ技術などがあります。ナノ技術とバイオインフォマティクスの調査も、診断検査の感度と特異度を画期的に向上させる道を記載しています。この市場の性質はダイナミックで競争的であるため、このセグメントの成長と関連性を維持するためには、常に注意を払い、新しい動向や技術に適応していく必要があります。

市場力学：急速に進化する分子診断における自動化市場の主要市場洞察を公開

分子診断における自動化市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性疾患罹患率の増加
  • 分子診断における精度とスピードの必要性
  • 個別化医療と精密医療への注目の高まり
• 市場抑制要因
  • 自動化技術に伴う初期投資の高さ
• 市場機会
  • 技術プロバイダーと分子診断薬企業間の協業活動の活発化
  • 医療インフラと研究における政府プログラムと資金援助
• 市場課題
  • 承認プロセスに関する厳しい規制

ポーターのファイブフォース：分子診断における自動化市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：分子診断における自動化市場における外部からの影響の把握

外部マクロ環境要因は、分子診断における自動化市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：分子診断における自動化市場における競合情勢の把握

分子診断における自動化市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：分子診断における自動化市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、分子診断における自動化市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：分子診断における自動化市場における成功への道筋を描く

分子診断における自動化市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で慢性疾患の発生率が増加
    • 分子診断における正確性とスピードの必要性
    • パーソナライズされた医療と精密医療への注目の高まり
  • 抑制要因
    • 自動化技術に関連する初期投資額が高い
  • 機会
    • 技術プロバイダーと分子診断企業間の協力活動の増加
    • 医療インフラと研究における政府のプログラムと資金
  • 課題
    • 承認プロセスに関連する厳格な規制
• 市場セグメンテーション分析
  • タイプ：高スループット設定における増幅自動化の重要性の高まり
  • 自動化タイプ：総合的なラボ自動化とモジュール型ソリューションによる分子診断の効率向上
  • 製品：分子診断のソフトウェアと機器への自動化の革新と統合
  • 用途：自動化により、がん、感染症、遺伝子検査、血液検査の精度が向上
  • 最終用途：研究機関は、高度にカスタマイズ可能で拡大可能な自動化ソリューションを好む
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 分子診断における自動化市場：タイプ別

• イントロダクション
• 増幅の自動化
• 分析の自動化
• 抽出の自動化
• 分析後の自動化
• 分析前の自動化

第7章 分子診断における自動化市場：自動化タイプ別

• イントロダクション
• モジュール型自動化
• トータルラボ型自動化

第8章 分子診断における自動化市場：製品別

• イントロダクション
• 装置
• サービス
• ソフトウェア

第9章 分子診断における自動化市場：用途別

• イントロダクション
• 血液検査
• 遺伝子検査
• 感染症
• 腫瘍学

第10章 分子診断における自動化市場：最終用途別

• イントロダクション
• 臨床検査室
• 病院
• 研究機関

第11章 南北アメリカの分子診断における自動化市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の分子診断における自動化市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの分子診断における自動化市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Biocare MedicalとMolecular Instrumentsが協力し、バイオイメージング技術の向上を目指す
  • Roche DiagnosticsとHitachi High-Tech、分子診断自動化の革新に向けて46年間の提携を延長
  • Bruker Corporation、診断能力強化のためELITechGroupを8億7,000万ユーロで買収
  • Devyser DiagnosticsとHamiltonが提携し、遺伝子検査ワークフローの自動化と強化を実現
  • Bosch HealthcareとRandoxがVivalytic分子診断プラットフォームの発展に1億5,900万米ドルを投資
  • HORIBA MedicalがHELO 2.0を発表、CE-IVDR承認を取得しFDA承認待ちの自動血液学検査を前進させる
  • 産業用微生物モニタリングを強化するLuminUltraのBugCount Guardianの発売
  • Yourgene Health、非侵襲性出生前検査を強化する革新的なMagBench技術を発表
  • Menarini DiagnosticsがPRIME MDxプラットフォームを発表、自動化分子診断に革命を起こす
  • Mylab Discovery SolutionsとAstraGene LLCが提携し、アラブ首長国連邦とクウェートで自動分子診断を推進
• 戦略分析と提言
  • F. Hoffmann-La Roche Ltd.
  • Meridian Bioscience, Inc.
  • Revvity, Inc.
  • Seegene Inc.

企業一覧

• Abbott Laboratories
• Adaltis S.r.l.
• Agilent Technologies, Inc.
• altona Diagnostics GmbH
• Aurora Biomed Inc.
• Becton, Dickinson and Company
• Biocartis NV
• bioMerieux SA
• Bruker Corporation
• Danaher Corporation
• DiaSorin S.p.A.
• Eppendorf SE
• F. Hoffmann-La Roche Ltd.
• Festo Corporation
• Hamilton Company
• Hologic, Inc.
• Hudson Robotics, Inc.
• LabVantage Solutions Inc.
• MEGAROBO technologies Co., Ltd.
• Meridian Bioscience, Inc.
• Molgen B.V.
• Mylab Discovery Solutions Pvt. Ltd.
• QIAGEN N.V.
• QuidelOrtho Corporation
• Revvity, Inc.
• Sansure BIoTech Inc.
• Scispot.io Inc.
• Seegene Inc.
• Siemens Healthineers AG
• Sysmex Corporation
• Tecan Group Ltd.
• Thermo Fisher Scientific Inc.
• Vela Diagnostics Holding Pte Ltd.
• Waters Corporation

LIST OF FIGURES

• FIGURE 1. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ANALYSIS AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXTRACTION AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY POST-ANALYTICAL AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRE-ANALYTICAL AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MODULAR AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TOTAL LAB AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. CANADA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. INDIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. ITALY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. POLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. QATAR AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION TYPE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 238. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Automation in the Molecular Diagnostics Market was valued at USD 11.75 billion in 2023, expected to reach USD 13.54 billion in 2024, and is projected to grow at a CAGR of 15.79%, to USD 32.81 billion by 2030.

Automation in molecular diagnostics refers to the integration of advanced technologies and automated systems to streamline and enhance the processes involved in the detection and analysis of molecules for various medical and research purposes. The necessity for automation in this field is driven by the need for higher precision, reduced errors, faster processing time, and increased throughput, which are crucial for responding effectively to the growing demand for diagnostic tests. Applications of automation span across sample preparation, assay development, data analysis, and result interpretation, significantly benefiting laboratories, hospitals, and research institutions. The end-use scope is expansive, catering to clinical diagnostics, drug discovery, personalized medicine, and epidemiology.

Market insights reveal that key growth factors include the rising prevalence of chronic diseases, increased demand for personalized medicine, and technological advancements in diagnostic equipment. Furthermore, emerging opportunities are presented by the integration of artificial intelligence and machine learning, which promise to revolutionize data interpretation and operational efficiency in diagnostic processes. Companies can capture these opportunities by investing in Research & Development for AI-driven platforms and by forming strategic partnerships to enhance expertise and market reach.

However, the market faces limitations such as high cost of implementation, regulatory hurdles, and ethical concerns surrounding data privacy and management. Addressing these challenges requires developing cost-effective solutions and robust cybersecurity measures, as well as a clear regulatory framework to ensure compliance.

Innovation areas ripe for exploration include the development of point-of-care testing solutions, improved biosensors, and lab-on-a-chip technologies that promise to decentralize and expedite diagnostic services. Research in nanotechnology and bioinformatics can also provide avenues for breakthrough improvements in sensitivity and specificity of diagnostic tests. The nature of this market is dynamic and competitive, necessitating constant vigilance and adaptability to new trends and technologies to sustain growth and relevance in the field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Automation in the Molecular Diagnostics Market

The Automation in the Molecular Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of chronic diseases across the globe
  • Need for accuracy and speed in molecular diagnostics
  • Rising focus on personalized healthcare and precision medicine
• Market Restraints
  • High initial investment associated with automation technology
• Market Opportunities
  • Rising collaborative activities among technology providers and molecular diagnostics companies
  • Government programs and funding in healthcare infrastructure and research
• Market Challenges
  • Stringent regulations associated with the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Automation in the Molecular Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Automation in the Molecular Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Automation in the Molecular Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Automation in the Molecular Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Automation in the Molecular Diagnostics Market

A detailed market share analysis in the Automation in the Molecular Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Automation in the Molecular Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Automation in the Molecular Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Automation in the Molecular Diagnostics Market

A strategic analysis of the Automation in the Molecular Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Automation in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaltis S.r.l., Agilent Technologies, Inc., altona Diagnostics GmbH, Aurora Biomed Inc., Becton, Dickinson and Company, Biocartis NV, bioMerieux SA, Bruker Corporation, Danaher Corporation, DiaSorin S.p.A., Eppendorf SE, F. Hoffmann-La Roche Ltd., Festo Corporation, Hamilton Company, Hologic, Inc., Hudson Robotics, Inc., LabVantage Solutions Inc., MEGAROBO technologies Co., Ltd., Meridian Bioscience, Inc., Molgen B.V., Mylab Discovery Solutions Pvt. Ltd., QIAGEN N.V., QuidelOrtho Corporation, Revvity, Inc., Sansure Biotech Inc., Scispot.io Inc., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Tecan Group Ltd., Thermo Fisher Scientific Inc., Vela Diagnostics Holding Pte Ltd., and Waters Corporation.

Market Segmentation & Coverage

This research report categorizes the Automation in the Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Amplification Automation, Analysis Automation, Extraction Automation, Post-analytical Automation, and Pre-analytical Automation.
• Based on Automation Type, market is studied across Modular Automation and Total Lab Automation.
• Based on Product, market is studied across Equipment, Services, and Software.
• Based on Application, market is studied across Blood Screening, Genetic Testing, Infectious Diseases, and Oncology.
• Based on End-use, market is studied across Clinical Laboratories, Hospitals, and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of chronic diseases across the globe
    • 5.1.1.2. Need for accuracy and speed in molecular diagnostics
    • 5.1.1.3. Rising focus on personalized healthcare and precision medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High initial investment associated with automation technology
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising collaborative activities among technology providers and molecular diagnostics companies
    • 5.1.3.2. Government programs and funding in healthcare infrastructure and research
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations associated with the approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing significance of amplification automation in high-throughput settings
  • 5.2.2. Automation Type: Enhancing efficiency in molecular diagnostics with total lab automation and modular solutions
  • 5.2.3. Product: Revolutionizing and integrating the automation into the software and equipment of molecular diagnostics
  • 5.2.4. Application: Automation enhances precision in cancer, infectious disease, genetic testing, and blood screening
  • 5.2.5. End-use: Research institutions prefer highly customizable and scalable automation solutions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Automation in the Molecular Diagnostics Market, by Type

• 6.1. Introduction
• 6.2. Amplification Automation
• 6.3. Analysis Automation
• 6.4. Extraction Automation
• 6.5. Post-analytical Automation
• 6.6. Pre-analytical Automation

7. Automation in the Molecular Diagnostics Market, by Automation Type

• 7.1. Introduction
• 7.2. Modular Automation
• 7.3. Total Lab Automation

8. Automation in the Molecular Diagnostics Market, by Product

• 8.1. Introduction
• 8.2. Equipment
• 8.3. Services
• 8.4. Software

9. Automation in the Molecular Diagnostics Market, by Application

• 9.1. Introduction
• 9.2. Blood Screening
• 9.3. Genetic Testing
• 9.4. Infectious Diseases
• 9.5. Oncology

10. Automation in the Molecular Diagnostics Market, by End-use

• 10.1. Introduction
• 10.2. Clinical Laboratories
• 10.3. Hospitals
• 10.4. Research Institutions

11. Americas Automation in the Molecular Diagnostics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Automation in the Molecular Diagnostics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Automation in the Molecular Diagnostics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Biocare Medical and Molecular Instruments Join Forces to Elevate Bioimaging Technologies
  • 14.3.2. Roche Diagnostics and Hitachi High-Tech Extend 46-Year Partnership to Innovate Molecular Diagnostic Automation
  • 14.3.3. Bruker Corporation Acquires ELITechGroup for EUR 870 million to Boost Diagnostic Capabilities
  • 14.3.4. Devyser Diagnostics and Hamilton Partner to Automate and Enhance Genetic Testing Workflows
  • 14.3.5. Bosch Healthcare and Randox Invest USD 159 Million to Advance Vivalytic Molecular Diagnostics Platform
  • 14.3.6. HORIBA Medical Unveils HELO 2.0, Advancing Automated Hematology with CE-IVDR Approval and Awaiting FDA Nod
  • 14.3.7. The Launch of BugCount Guardian by LuminUltra to Enhnace Industrial Microbial Monitoring
  • 14.3.8. Yourgene Health Unveils Revolutionary MagBench Technology for Enhanced Non-Invasive Prenatal Testing
  • 14.3.9. Menarini Diagnostics Launches PRIME MDx Platform, Revolutionizing Automated Molecular Diagnostics
  • 14.3.10. Mylab Discovery Solutions and AstraGene LLC Form Partnership to Advance Automated Molecular Diagnostics in UAE and Kuwait
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. F. Hoffmann-La Roche Ltd.
  • 14.4.2. Meridian Bioscience, Inc.
  • 14.4.3. Revvity, Inc.
  • 14.4.4. Seegene Inc.

Companies Mentioned

• 1. Abbott Laboratories
• 2. Adaltis S.r.l.
• 3. Agilent Technologies, Inc.
• 4. altona Diagnostics GmbH
• 5. Aurora Biomed Inc.
• 6. Becton, Dickinson and Company
• 7. Biocartis NV
• 8. bioMerieux SA
• 9. Bruker Corporation
• 10. Danaher Corporation
• 11. DiaSorin S.p.A.
• 12. Eppendorf SE
• 13. F. Hoffmann-La Roche Ltd.
• 14. Festo Corporation
• 15. Hamilton Company
• 16. Hologic, Inc.
• 17. Hudson Robotics, Inc.
• 18. LabVantage Solutions Inc.
• 19. MEGAROBO technologies Co., Ltd.
• 20. Meridian Bioscience, Inc.
• 21. Molgen B.V.
• 22. Mylab Discovery Solutions Pvt. Ltd.
• 23. QIAGEN N.V.
• 24. QuidelOrtho Corporation
• 25. Revvity, Inc.
• 26. Sansure Biotech Inc.
• 27. Scispot.io Inc.
• 28. Seegene Inc.
• 29. Siemens Healthineers AG
• 30. Sysmex Corporation
• 31. Tecan Group Ltd.
• 32. Thermo Fisher Scientific Inc.
• 33. Vela Diagnostics Holding Pte Ltd.
• 34. Waters Corporation